Cargando…
Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and e...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984672/ https://www.ncbi.nlm.nih.gov/pubmed/24292886 http://dx.doi.org/10.1007/s00401-013-1217-3 |
_version_ | 1782311464880570368 |
---|---|
author | Kastenhuber, Edward R. Huse, Jason T. Berman, Samuel H. Pedraza, Alicia Zhang, Jianan Suehara, Yoshiyuki Viale, Agnes Cavatore, Magali Heguy, Adriana Szerlip, Nicholas Ladanyi, Marc Brennan, Cameron W. |
author_facet | Kastenhuber, Edward R. Huse, Jason T. Berman, Samuel H. Pedraza, Alicia Zhang, Jianan Suehara, Yoshiyuki Viale, Agnes Cavatore, Magali Heguy, Adriana Szerlip, Nicholas Ladanyi, Marc Brennan, Cameron W. |
author_sort | Kastenhuber, Edward R. |
collection | PubMed |
description | Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and expression levels of common RTK deletion mutants in glioblastoma, we analyzed RNA from a set of 192 glioblastoma samples from The Cancer Genome Atlas for the expression of EGFRvIII, EGFRvII, EGFRvV (carboxyl-terminal deletion), and PDGFRAΔ8,9. These mutations were detected in 24, 1.6, 4.7, and 1.6 % of cases, respectively. Overall, 29 % (55/189) of glioblastomas expressed at least one RTK intragenic deletion transcript in this panel. For EGFRvIII, samples were analyzed by both quantitative real-time PCR (QRT-PCR) and single mRNA molecule counting on the Nanostring nCounter platform. Nanostring proved to be highly sensitive, specific, and linear, with sensitivity comparable or exceeding that of RNA seq. We evaluated the prognostic significance and molecular correlates of RTK rearrangements. EGFRvIII was only detectable in tumors with focal amplification of the gene. Moreover, we found that EGFRvIII expression was not prognostic of poor outcome and that neither recurrent copy number alterations nor global changes in gene expression differentiate EGFRvIII-positive tumors from tumors with amplification of wild-type EGFR. The wide range of expression of mutant alleles and co-expression of multiple EGFR variants suggests that quantitative RNA-based clinical assays will be important for assessing the relative expression of intragenic deletions as therapeutic targets and/or candidate biomarkers. To this end, we demonstrate the performance of the Nanostring assay in RNA derived from routinely collected formalin-fixed paraffin-embedded tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-013-1217-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3984672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-39846722014-04-23 Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates Kastenhuber, Edward R. Huse, Jason T. Berman, Samuel H. Pedraza, Alicia Zhang, Jianan Suehara, Yoshiyuki Viale, Agnes Cavatore, Magali Heguy, Adriana Szerlip, Nicholas Ladanyi, Marc Brennan, Cameron W. Acta Neuropathol Original Paper Intragenic deletion is the most common form of activating mutation among receptor tyrosine kinases (RTK) in glioblastoma. However, these events are not detected by conventional DNA sequencing methods commonly utilized for tumor genotyping. To comprehensively assess the frequency, distribution, and expression levels of common RTK deletion mutants in glioblastoma, we analyzed RNA from a set of 192 glioblastoma samples from The Cancer Genome Atlas for the expression of EGFRvIII, EGFRvII, EGFRvV (carboxyl-terminal deletion), and PDGFRAΔ8,9. These mutations were detected in 24, 1.6, 4.7, and 1.6 % of cases, respectively. Overall, 29 % (55/189) of glioblastomas expressed at least one RTK intragenic deletion transcript in this panel. For EGFRvIII, samples were analyzed by both quantitative real-time PCR (QRT-PCR) and single mRNA molecule counting on the Nanostring nCounter platform. Nanostring proved to be highly sensitive, specific, and linear, with sensitivity comparable or exceeding that of RNA seq. We evaluated the prognostic significance and molecular correlates of RTK rearrangements. EGFRvIII was only detectable in tumors with focal amplification of the gene. Moreover, we found that EGFRvIII expression was not prognostic of poor outcome and that neither recurrent copy number alterations nor global changes in gene expression differentiate EGFRvIII-positive tumors from tumors with amplification of wild-type EGFR. The wide range of expression of mutant alleles and co-expression of multiple EGFR variants suggests that quantitative RNA-based clinical assays will be important for assessing the relative expression of intragenic deletions as therapeutic targets and/or candidate biomarkers. To this end, we demonstrate the performance of the Nanostring assay in RNA derived from routinely collected formalin-fixed paraffin-embedded tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-013-1217-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-11-29 2014 /pmc/articles/PMC3984672/ /pubmed/24292886 http://dx.doi.org/10.1007/s00401-013-1217-3 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Paper Kastenhuber, Edward R. Huse, Jason T. Berman, Samuel H. Pedraza, Alicia Zhang, Jianan Suehara, Yoshiyuki Viale, Agnes Cavatore, Magali Heguy, Adriana Szerlip, Nicholas Ladanyi, Marc Brennan, Cameron W. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
title | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
title_full | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
title_fullStr | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
title_full_unstemmed | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
title_short | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
title_sort | quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984672/ https://www.ncbi.nlm.nih.gov/pubmed/24292886 http://dx.doi.org/10.1007/s00401-013-1217-3 |
work_keys_str_mv | AT kastenhuberedwardr quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT husejasont quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT bermansamuelh quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT pedrazaalicia quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT zhangjianan quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT sueharayoshiyuki quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT vialeagnes quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT cavatoremagali quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT heguyadriana quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT szerlipnicholas quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT ladanyimarc quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates AT brennancameronw quantitativeassessmentofintragenicreceptortyrosinekinasedeletionsinprimaryglioblastomastheirprevalenceandmolecularcorrelates |